Rangeley Capital’s Mersana Therapeutics MRSN Stock Holding History

Rangeley Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,098	Closed	-$1.65M	–	150
2025 Q4	$1.65M	Buy	+57,098	New	+$1.08M	1.37%	24

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rangeley Capital's MRSN Position: Q1 2026 in Review

Rangeley Capital sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 57,098 shares — an estimated $1.65M sold.

Rangeley Capital first reported a position in MRSN in Q4 2025 and held it in 1 quarter. The position peaked at $1.65M in Q4 2025. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

Rangeley Capital reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
Rangeley Capital sold 57,098 Mersana Therapeutics shares in Q1 2026, an estimated $1.65M.
Rangeley Capital first reported a position in Mersana Therapeutics in Q4 2025 and held it in 1 quarter.
Rangeley Capital's Mersana Therapeutics position peaked at $1.65M in Q4 2025.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.